AbbVie (NYSE: ABBV) announced today that SKYRIZI® (risankizumab) is now available in Canada for the treatment of adults with moderately to severely active ulcerative colitis (UC) who have had an ...

AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue forecast of $31 billion for both drugs.

Skyrizi is a prescription drug that treats plaque psoriasis, psoriatic arthritis, and Crohn's disease. Learn how Skyrizi works and how long it takes to start working.

Learn about dosage, side effects, and more of Skyrizi (risankizumab-rzaa), which is a prescription injection used to treat plaque psoriasis.

Skyrizi was the top Rx and over-the-counter (OTC) pharma brand during July, according to data released by iSpot.tv on Monday afternoon. Skyrizi recorded an impressions share of voice (SOV) of 5.18%, ...

Skyrizi is the first treatment of its kind, an IL-23, or interleukin-23-specific inhibitor, approved for use on moderate to severe ulcerative colitis and moderate to severe Crohn's disease.

Skyrizi came out on top with the latest quarterly crown for over-the-counter (OTC) pharma and Rx brands. The AbbVie treatment for psoriasis, Crohn’s disease and psoriatic arthritis finished in first ...

The FDA has given its okay to the biologic drug Skyrizi (risankizumab) as a treatment for people with moderately to severely active ulcerative colitis. The medication works by blocking the immune ...

The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, making it the first interleukin-23 specific inhibitor approved for both UC and Crohn ...

AbbVie won approval for Skyrizi in Crohn’s disease, an adjacent indication to ulcerative colitis, in 2022 and has heavily promoted the drug.

Researchers from King’s College London (KCL) have investigated the early effects of AbbVie’s immunosuppressant drug, Skyrizi (risankizumab), which could help clinicians develop personalised treatment ...